Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07277660

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Led by UCB Biopharma SRL · Updated on 2026-05-08

160

Participants Needed

57

Research Sites

114 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

CONDITIONS

Official Title

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must be aged greater than or equal (≥) 18 years at the time of signing the informed consent
  • Participant has chronic atopic dermatitis present for at least 1 year prior to starting the study
  • Validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline
  • Eczema Area and Severity Index (EASI) score ≥16 at both Screening and Baseline
  • Peak Pruritus Numerical Rating Scale (PP-NRS) score of ≥4 at both Screening and Baseline
  • Atopic dermatitis involvement of ≥10% body surface area at both Screening and Baseline
  • Documented recent history (within 6 months prior to Screening) of inadequate response to topical treatments or topical treatments medically inadvisable and candidate for systemic therapy
Not Eligible

You will not qualify if you...

  • History or presence of medical or psychiatric conditions that pose a risk or interfere with study participation
  • Active dermatologic conditions that could confuse diagnosis or interfere with treatment assessment
  • Presence or family history of inflammatory bowel disease
  • History of chronic or serious infections within 6 months prior to Baseline
  • Meeting tuberculosis exclusion criteria
  • Previous treatment with galvokimig
  • Relevant safety events from interleukin-13 biologic response modifiers requiring treatment change
  • Use of systemic therapies (except biologics), topical therapies, or other treatments for atopic dermatitis within 4 weeks prior to Baseline
  • Use of biologic agents within 3 months prior to Baseline

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 57 locations

1

Atd002 52021

Oceanside, California, United States, 92056

Actively Recruiting

2

Atd002 52008

Santa Monica, California, United States, 90404

Actively Recruiting

3

Atd002 52013

Boca Raton, Florida, United States, 33486

Actively Recruiting

4

Atd002 52007

Coral Gables, Florida, United States, 33134

Actively Recruiting

5

Atd002 52003

Miami, Florida, United States, 33133

Actively Recruiting

6

Atd002 52015

Savannah, Georgia, United States, 31419

Actively Recruiting

7

Atd002 52017

Chicago, Illinois, United States, 60611

Actively Recruiting

8

Atd002 52018

Wheaton, Illinois, United States, 60189

Actively Recruiting

9

Atd002 52012

New Albany, Indiana, United States, 47150

Actively Recruiting

10

Atd002 52014

Bowling Green, Kentucky, United States, 42104

Actively Recruiting

11

Atd002 52001

Troy, Michigan, United States, 48084

Actively Recruiting

12

Atd002 52009

Troy, Michigan, United States, 48084

Actively Recruiting

13

Atd002 52010

Omaha, Nebraska, United States, 68144

Actively Recruiting

14

Atd002 52020

The Bronx, New York, United States, 10455

Actively Recruiting

15

Atd002 52019

Philadelphia, Pennsylvania, United States, 19114

Actively Recruiting

16

Atd002 52005

Dallas, Texas, United States, 75230

Actively Recruiting

17

Atd002 52016

Frisco, Texas, United States, 75033

Actively Recruiting

18

Atd002 52011

Frisco, Texas, United States, 75034

Actively Recruiting

19

Atd002 52004

Sugar Land, Texas, United States, 77479

Actively Recruiting

20

Atd002 41004

Lovech, Bulgaria

Actively Recruiting

21

Atd002 41001

Pleven, Bulgaria

Actively Recruiting

22

Atd002 41007

Plovdiv, Bulgaria

Actively Recruiting

23

Atd002 41002

Sevlievo, Bulgaria

Actively Recruiting

24

Atd002 41005

Sofia, Bulgaria

Actively Recruiting

25

Atd002 41006

Sofia, Bulgaria

Actively Recruiting

26

Atd002 51006

Hamilton, Canada

Actively Recruiting

27

Atd002 51007

Toronto, Canada

Actively Recruiting

28

Atd002 42002

Náchod, Czechia

Actively Recruiting

29

Atd002 42001

Prague, Czechia

Actively Recruiting

30

Atd002 42004

Prague, Czechia

Actively Recruiting

31

Atd002 42005

Prague, Czechia

Actively Recruiting

32

Atd002 43001

Bad Bentheim, Germany

Actively Recruiting

33

Atd002 43002

Frankfurt, Germany

Actively Recruiting

34

Atd002 43004

Leipzig, Germany

Actively Recruiting

35

Atd002 43007

Mahlow, Germany

Actively Recruiting

36

Atd002 44003

Budapest, Hungary

Actively Recruiting

37

Atd002 21001

Habikino, Japan

Actively Recruiting

38

Atd002 21007

Nagoya, Japan

Actively Recruiting

39

Atd002 21005

Sakai, Japan

Actively Recruiting

40

Atd002 21008

Sapporo, Japan

Actively Recruiting

41

Atd002 21004

Tachikawa-shi, Japan

Actively Recruiting

42

Atd002 21006

Yokohama, Japan

Actively Recruiting

43

Atd002 45001

Katowice, Poland

Actively Recruiting

44

Atd002 45003

Krakow, Poland

Actively Recruiting

45

Atd002 45007

Krakow, Poland

Actively Recruiting

46

Atd002 45010

Krakow, Poland

Actively Recruiting

47

Atd002 45014

Krakow, Poland

Actively Recruiting

48

Atd002 45013

Lodz, Poland

Actively Recruiting

49

Atd002 45005

Sosnowiec, Poland

Actively Recruiting

50

Atd002 45009

Tarnów, Poland

Actively Recruiting

51

Atd002 45002

Warsaw, Poland

Actively Recruiting

52

Atd002 45004

Warsaw, Poland

Actively Recruiting

53

Atd002 45006

Warsaw, Poland

Actively Recruiting

54

Atd002 45008

Wroclaw, Poland

Actively Recruiting

55

Atd002 46004

London, United Kingdom

Actively Recruiting

56

Atd002 46007

London, United Kingdom

Actively Recruiting

57

Atd002 46003

Salford, United Kingdom

Actively Recruiting

Loading map...

Research Team

U

UCB Cares

CONTACT

U

UCB Cares

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here